Skip to main content
. 2022 Mar 1;12:3384. doi: 10.1038/s41598-022-07247-8

Figure 6.

Figure 6

Drug candidates with nitro-hydroxy and two hydroxy substituted phenylamide moiety. (A) Cell viability (MTT assay) following exposure to modified variants of HR48 with one hydroxy and one nitro group or with two hydroxy groups in the phenylamide moiety (25 μM, for 72 h). (B) CV cell viability (% of control) mean ± SD at 25 μM; ClogP calculated partitioning; HBD hydrogen bond donor at pH 7; HBA hydrogen bond acceptor at pH 7; logBB calculated blood–brain partition; PSA polar surface area (Å2); MPA minimal projection area (Å2); logS aqueous solubility (mg/mL); MPO Central nervous system multiparameter optimization (CNS MPO). (C) Electrostatic potential map for H56-HR59. (D) Computed LUMO + 1 orbitals contribution with their energies. (E) Computed LUMO orbitals contribution with their energies. (F) Computed HOMO orbitals contribution with their energies generated by semi-empirical method PM3 as implemented in Spartan ’18 version 1.1.0.